These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24975049)

  • 1. Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.
    Wakamatsu T; Naka N; Sasagawa S; Tanaka T; Takenaka S; Araki N; Ueda T; Nishizawa Y; Yoshikawa H; Itoh K
    Cancer Sci; 2014 Sep; 105(9):1124-34. PubMed ID: 24975049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
    Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
    Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
    Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SS18-SSX drives CREB activation in synovial sarcoma.
    Cyra M; Schulte M; Berthold R; Heinst L; Jansen EP; Grünewald I; Elges S; Larsson O; Schliemann C; Steinestel K; Hafner S; Simmet T; Wardelmann E; Kailayangiri S; Rossig C; Isfort I; Trautmann M; Hartmann W
    Cell Oncol (Dordr); 2022 Jun; 45(3):399-413. PubMed ID: 35556229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.
    Yoneda Y; Ito S; Kunisada T; Morimoto Y; Kanzaki H; Yoshida A; Shimizu K; Ozaki T; Ouchida M
    PLoS One; 2013; 8(10):e77564. PubMed ID: 24130893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATR Is a Therapeutic Target in Synovial Sarcoma.
    Jones SE; Fleuren EDG; Frankum J; Konde A; Williamson CT; Krastev DB; Pemberton HN; Campbell J; Gulati A; Elliott R; Menon M; Selfe JL; Brough R; Pettitt SJ; Niedzwiedz W; van der Graaf WTA; Shipley J; Ashworth A; Lord CJ
    Cancer Res; 2017 Dec; 77(24):7014-7026. PubMed ID: 29038346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma.
    Baranov E; McBride MJ; Bellizzi AM; Ligon AH; Fletcher CDM; Kadoch C; Hornick JL
    Am J Surg Pathol; 2020 Jul; 44(7):922-933. PubMed ID: 32141887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.
    Su L; Sampaio AV; Jones KB; Pacheco M; Goytain A; Lin S; Poulin N; Yi L; Rossi FM; Kast J; Capecchi MR; Underhill TM; Nielsen TO
    Cancer Cell; 2012 Mar; 21(3):333-47. PubMed ID: 22439931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
    Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
    Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma.
    Raquib AR; Hofvander J; Ta M; Nielsen TO
    Appl Immunohistochem Mol Morphol; 2022 Sep; 30(8):531-539. PubMed ID: 35880992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth.
    Törnkvist M; Natalishvili N; Xie Y; Girnita A; D'Arcy P; Brodin B; Axelson M; Girnita L
    Biochem Biophys Res Commun; 2008 Apr; 368(3):793-800. PubMed ID: 18267106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When used together SS18-SSX fusion-specific and SSX C-terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases.
    Zaborowski M; Vargas AC; Pulvers J; Clarkson A; de Guzman D; Sioson L; Maclean F; Chou A; Gill AJ
    Histopathology; 2020 Oct; 77(4):588-600. PubMed ID: 32559341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo.
    Takenaka S; Naka N; Araki N; Hashimoto N; Ueda T; Yoshioka K; Yoshikawa H; Itoh K
    Int J Oncol; 2010 Apr; 36(4):823-31. PubMed ID: 20198325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic signatures corresponding to the SS18/SSX fusion gene in synovial sarcoma.
    Ishii M; Suehara Y; Sano K; Kohsaka S; Hayashi T; Kazuno S; Akaike K; Mukaihara K; Kim Y; Okubo T; Takamochi K; Takahashi F; Kaneko K; Saito T
    Oncotarget; 2018 Dec; 9(101):37509-37519. PubMed ID: 30680066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.
    Minami Y; Kohsaka S; Tsuda M; Yachi K; Hatori N; Tanino M; Kimura T; Nishihara H; Minami A; Iwasaki N; Tanaka S
    Cancer Sci; 2014 Sep; 105(9):1152-9. PubMed ID: 24989082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.
    Li J; Mulvihill TS; Li L; Barrott JJ; Nelson ML; Wagner L; Lock IC; Pozner A; Lambert SL; Ozenberger BB; Ward MB; Grossmann AH; Liu T; Banito A; Cairns BR; Jones KB
    Cancer Discov; 2021 Oct; 11(10):2620-2637. PubMed ID: 34078620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma.
    Peng C; Zhao H; Chen W; Song Y; Wang X; Li J; Qiao Y; Wu D; Ma S; Wang X; Gao C
    Oncotarget; 2016 Oct; 7(41):66822-66834. PubMed ID: 27572315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.
    Carmody Soni EE; Schlottman S; Erkizan HV; Uren A; Toretsky JA
    Clin Orthop Relat Res; 2014 Mar; 472(3):874-82. PubMed ID: 23716114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoreactivity of a Monoclonal Antibody to SS18-SSX Fusion Gene Product in Formalin-fixed Paraffin-embedded Synovial Sarcoma Tissue Section.
    Saigo C; Kito Y; Takeuchi T
    Appl Immunohistochem Mol Morphol; 2018 Mar; 26(3):206-211. PubMed ID: 27362474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.